Se - [(2,2-Dimethyl-1,3-dioxolan-4-yl) methyl] 4-chlorobenzoselenolate reduces the nociceptive and edematogenic response by chemical noxious stimuli in mice: Implications of multi-target actions

Wilhelm, Ethel A.; Soares, Paola S.; Reis, Angélica S.; Barth, Anelise; Freitas, Bárbara Guimaraes de; Motta, Ketlyn P. da; Lemos, Briana B.; Vogt, Ane G.; Fonseca, Caren A.R. da; Araujo, Daniela R.; Barcellos, Angelita M.; Perin, Gelson

doi:10.1016/j.pharep.2019.07.003

Cited by 5 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously reported by our research group, Se-[(2,2dimethyl-1,3-dioxolan-4-yl)methyl] 4-chlorobenzoselenolate (Se-DMC) can reduce nociceptive and edematogenic responses to toxic chemical stimuli in mice, 17 and its multitarget profile appears to be accountable for these pharmacological activities. Notably, the anti-inflammatory and antioxidant properties exert through the modulation of serotonergic and glutamatergic systems were partly responsible for the antinociceptive and antiedematogenic effects of Se-DMC.…”

Section: Introductionsupporting

confidence: 53%

“…In line with this, these findings further validate that Se-DMC is a promising molecule for RA therapy. More recently, our research group proved that Se-DMC exerts in vitro antioxidant activity, 17 in addition to antinociceptive and antiedematogenic effects on preclinical models, possibly through serotonergic and glutamatergic pathways and anti-inflammatory and antioxidant activities. 17 Additionally, Se-DMC treatment reduced nociception induced by glutamate or acetic acid and decreased paw edema development induced by glutamate, while meloxicam did not produce any effects.…”

Section: Resultsmentioning

confidence: 98%

“…More recently, our research group proved that Se-DMC exerts in vitro antioxidant activity, 17 in addition to antinociceptive and antiedematogenic effects on preclinical models, possibly through serotonergic and glutamatergic pathways and anti-inflammatory and antioxidant activities. 17 Additionally, Se-DMC treatment reduced nociception induced by glutamate or acetic acid and decreased paw edema development induced by glutamate, while meloxicam did not produce any effects. Se-DMC inhibited ear edema formation and reversed increased ear myeloperoxidase activity induced by a phlogistic agent in mice.…”

Section: Resultsmentioning

confidence: 98%

“…Notably, the anti-inflammatory and antioxidant properties exert through the modulation of serotonergic and glutamatergic systems were partly responsible for the antinociceptive and antiedematogenic effects of Se-DMC. 17 Nevertheless, there are no known investigations that evaluate the effects of Se-DMC in Freund's adjuvant (CFA)induced inflammatory joint conditions in RA. 18 Thus, given our growing interest in the pharmacology of this molecule, this study sought to evaluate the therapeutic potential of Se-DMC in joint inflammation and other RA-associated comorbidities in a mouse monoarthritis model.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Se-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl] 4-Chlorobenzoselenolate Attenuates Inflammatory Response, Nociception, and Affective Disorders Related to Rheumatoid Arthritis in Mice

Wilhelm

Soares

Reis

et al. 2021

ACS Chem. Neurosci.

Self Cite

View full text Add to dashboard Cite

Despite major advances, not all patients achieve rheumatoid arthritis (RA) remission, thus highlighting a pressing need for new therapeutic treatments. Given this scenario, this study sought to evaluate Se-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl] 4chlorobenzoselenolate (Se-DMC) potential on a complete Freund's adjuvant (CFA)-induced unilateral arthritis model. The effects of Se-DMC (5 mg/kg; oral dose) and meloxicam (5 mg/kg; oral dose), both administered to animals daily for 14 days, on paw edema, mechanical sensitivity, neurobehavioral deficits (anxiogenic-and depressive-like behaviors), Na + /K + -ATPase activity, oxidative stress, and inflammation were evaluated in male Swiss mice exposed to CFA (intraplantar injection of 0.1 mL; 10 mg/ mL). Se-DMC reduced the paw withdrawal threshold and CFA-induced paw edema. Histopathological results revealed the antiedematogenic potential of the compound, which was evidenced by lower quantities of dilated lymphatic vessels compared with the CFA group. Se-DMC reduced mRNA relative expression levels of tumor necrosis factor-α (TNF-α) and nuclear factor-κB (NF-κB) in the hippocampus and paw of CFA mice. The CFA-induced anxiogenic-and depressive-like behaviors were reversed by Se-DMC to the control levels in the elevated plus-maze and tail suspension tests. Se-DMC reduced the paw reactive species levels and restored the superoxide dismutase (hippocampus and paw) and Na + /K + -ATPase (hippocampus) activities previously increased by CFA. Moreover, CFA administration inhibited serum creatinine kinase activity, albeit the Se-DMC effects did not appear to involve the modulation of this enzyme and were equal to or greater than meloxicam. Se-DMC attenuates CFA-induced inflammatory response, nociception, and neurobehavioral deficits in mice.

show abstract

Section: Introductionsupporting

confidence: 53%

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Se-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl] 4-Chlorobenzoselenolate Attenuates Inflammatory Response, Nociception, and Affective Disorders Related to Rheumatoid Arthritis in Mice

Wilhelm

Soares

Reis

et al. 2021

ACS Chem. Neurosci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In agreement with our findings, previous studies also demonstrated that the meloxicam (10 and 50 mg/kg, ig) was ineffective in reduce the paw edema formation in the formalin and glutamate tests in mice, respectively. [63,64] Despite the difficulties in explaining why meloxicam did not reduce edema formation, it is possible that the selected treatment time (0.5 h) might not be appropriate for this NSAID to inhibit prostaglandin biosynthesis and thus, it exhibits an anti-inflammatory action.…”

Section: Biological Evaluationmentioning

confidence: 99%

Synthesis of 2‐Organylchalcogenopheno[2,3‐b]pyridines from Elemental Chalcogen and NaBH₄/PEG‐400 as a Reducing System: Antioxidant and Antinociceptive Properties

et al. 2020

Self Cite

View full text Add to dashboard Cite

An alternative method to prepare 2‐organylchalcogenopheno[2,3‐b]pyridines was developed by the insertion of chalcogen species (selenium, sulfur or tellurium), generated in situ, into 2‐chloro‐3‐(organylethynyl)pyridines by using the NaBH4/PEG‐400 reducing system, followed by an intramolecular cyclization. It was possible to obtain a series of compounds with up to 93 % yield in short reaction times. Among the synthesized products, 2‐organyltelluropheno[2,3‐b]pyridines have not been described in the literature so far. Moreover, the compounds 2‐phenylthieno[2,3‐b]pyridine (3 b) and 2‐phenyltelluropheno[2,3‐b]pyridine (3 c) exhibited significant antioxidant potential in different in vitro assays. Further studies demonstrated that compound 3 b exerted an antinociceptive effect in acute inflammatory and non‐inflammatory pain models, thus indicating the involvement of the central and peripheral nervous systems on its pharmacological action. More specifically, our results suggest that the intrinsic antioxidant property of compound 3 b might contribute to attenuating the nociception and inflammatory process on local injury induced by complete Freund's adjuvant (CFA).

show abstract

Synthesis and Evaluation of Antioxidant, Anti‐Edematogenic and Antinociceptive Properties of Selenium‐Sulfa Compounds

et al. 2021

Self Cite

View full text Add to dashboard Cite

Herein we describe results for the synthesis and synthetic application of 4‐amino‐3‐(arylselenyl)benzenesulfonamides, and preliminary evaluation of antioxidant, anti‐edematogenic and antinociceptive properties. This class of compounds was synthesized in good yields by a reaction of commercially available sulfanilamide and diorganyl diselenides in the presence of 10 mol% of I2. Furthermore, the synthesized compound 4‐amino‐3‐(phenylselenyl)benzenesulfonamide (3 a) was evaluated on complete Freund's adjuvant (CFA)‐induced acute inflammatory pain. Dose‐ and time‐response curves of antinociceptive effect of compound 3 a were performed using this experimental model. Also, the effect of compound 3 a was monitored in a hot‐plate test to evaluate the acute non‐inflammatory antinociception. The open‐field test was performed to evaluate the locomotor and exploratory behaviors of mice. Oxidative stress markers, such as glutathione peroxidase activity; reactive species, non‐protein thiols, and lipid peroxidation levels were performed to investigate the antioxidant action of compound 3 a. Our findings suggest that the antioxidant effect of compound 3 a may contribute to reducing the nociception and suppress the signaling pathways of inflammation on the local injury induced by CFA. Thus, compound 3 a reduced the paw edema as well as the hyperalgesic behavior in mice, being a promising therapeutic agent for the treatment of painful conditions.

show abstract

Se - [(2,2-Dimethyl-1,3-dioxolan-4-yl) methyl] 4-chlorobenzoselenolate reduces the nociceptive and edematogenic response by chemical noxious stimuli in mice: Implications of multi-target actions

Cited by 5 publications

References 45 publications

Se-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl] 4-Chlorobenzoselenolate Attenuates Inflammatory Response, Nociception, and Affective Disorders Related to Rheumatoid Arthritis in Mice

Se-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl] 4-Chlorobenzoselenolate Attenuates Inflammatory Response, Nociception, and Affective Disorders Related to Rheumatoid Arthritis in Mice

Synthesis of 2‐Organylchalcogenopheno[2,3‐b]pyridines from Elemental Chalcogen and NaBH₄/PEG‐400 as a Reducing System: Antioxidant and Antinociceptive Properties

Synthesis and Evaluation of Antioxidant, Anti‐Edematogenic and Antinociceptive Properties of Selenium‐Sulfa Compounds

Contact Info

Product

Resources

About

Se - [(2,2-Dimethyl-1,3-dioxolan-4-yl) methyl] 4-chlorobenzoselenolate reduces the nociceptive and edematogenic response by chemical noxious stimuli in mice: Implications of multi-target actions

Cited by 5 publications

References 45 publications

Se-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl] 4-Chlorobenzoselenolate Attenuates Inflammatory Response, Nociception, and Affective Disorders Related to Rheumatoid Arthritis in Mice

Se-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl] 4-Chlorobenzoselenolate Attenuates Inflammatory Response, Nociception, and Affective Disorders Related to Rheumatoid Arthritis in Mice

Synthesis of 2‐Organylchalcogenopheno[2,3‐b]pyridines from Elemental Chalcogen and NaBH4/PEG‐400 as a Reducing System: Antioxidant and Antinociceptive Properties

Synthesis and Evaluation of Antioxidant, Anti‐Edematogenic and Antinociceptive Properties of Selenium‐Sulfa Compounds

Contact Info

Product

Resources

About

Synthesis of 2‐Organylchalcogenopheno[2,3‐b]pyridines from Elemental Chalcogen and NaBH₄/PEG‐400 as a Reducing System: Antioxidant and Antinociceptive Properties